Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Italian biotech BioXell grosses CHF57.8mm IPO

28 Jun 2006

Executive Summary

BioXell SPA (urological, CNS, and anti-inflammatory drug development) grossed CHF57.8mm ($46mm) through an initial public offering of 1.3mm new ordinary shares at CHF44 apiece on the SWX Swiss Exchange. The company sold the stock at the low end of its initially set range of CHF44-48 per share.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By